Chest CT Interpretation Report

Diagnostic Radiology — Incidental Pulmonary Nodule Workup

Report ID: MAA-CCT-1A6F08
Generated: May 20, 2026
Analysis: AI-Powered Image Interpretation

Patient Profile

Sex / Age:
Female, 58 years
Reason for scan:
Persistent cough > 6 weeks; chest X-ray showed possible nodule, prompting CT
Smoking history:
20 pack-years (smoked age 18–48), quit 10 years ago
Other history:
Hypertension, prior breast cancer (Stage I, 2018, no recurrence on surveillance)
Study:
Non-contrast chest CT, 1 mm reconstruction
Comparison:
No prior chest CT available; chest X-ray 6 weeks prior on file

Summary Overview

Chest CT identifies an 8 mm solid pulmonary nodule in the right upper lobe with smooth margins, no spiculation. No additional nodules. No mediastinal lymphadenopathy. No effusion. Lung-RADS category 3 / Fleischner Society high-risk solid 6–8 mm — surveillance imaging recommended.

8 mm
Solid Nodule
~5%
Malignancy Estimate
3
Lung-RADS

Risk Stratification Inputs

Patient risk category:
High-risk (former smoker, > 20 pack-years, age > 50, prior cancer history) [Fleischner Society 2017]
Nodule size:
8 mm (in 6–8 mm range — moderate concern)
Nodule character:
Solid, smooth-bordered, without spiculation, no cavitation
Brock model estimated probability of malignancy:
~5% (incorporating size, location, smoking, prior cancer) [McWilliams A, NEJM 2013]

Detailed Imaging Findings

Right Upper Lobe NoduleIndeterminate
Long axis
8 mm
Volume estimate
~270 mm³
Density / margins
Solid / smooth
Solitary subpleural solid nodule in the apicoposterior segment of the right upper lobe (RUL). Smooth, well-defined borders without spiculation, calcification pattern not benign-typical. No cavitation, no air bronchogram. Adjacent vasculature unremarkable. Indeterminate by morphology — requires interval follow-up [Fleischner Society 2017; Lung-RADS 1.1].
Other Lung ParenchymaNo Additional Nodule
Otherwise clear. No additional nodules > 4 mm. Mild mosaic attenuation in the lower lobes, non-specific. No tree-in-bud, no consolidation, no ground-glass.
Mediastinum / HilumNormal
No mediastinal or hilar lymphadenopathy (largest short-axis < 8 mm). Heart and great vessels unremarkable. No pericardial effusion.
Pleura / Bones / Upper AbdomenNormal
No pleural effusion or thickening. No osseous lesion. Imaged upper abdomen unremarkable; no liver or adrenal lesion.

Differential Diagnosis

  • Benign granuloma (post-infectious or non-specific)High
    Most solitary 6–8 mm solid nodules in this morphology are benign. Surveillance is the standard first step.
  • HamartomaModerate
    Smooth borders consistent; characteristic fat or popcorn calcification, when present, is diagnostic.
  • Primary lung malignancyLow–Moderate
    Risk modulated up by smoking, age, and prior breast cancer; Brock model estimate ~5%. Stability or growth on follow-up is the key discriminator [McWilliams A 2013].
  • Metastasis (e.g., from prior breast cancer)Low
    Solitary lesion 8 years post Stage I cancer is unusual but not impossible; surveillance imaging will inform.

Analytical Summary & Recommendations

Imaging impression

Solitary indeterminate 8 mm solid pulmonary nodule, RUL, in a former smoker with prior breast cancer. Lung-RADS category 3 / Fleischner Society high-risk solid 6–8 mm category — recommended action is structured surveillance, not immediate biopsy.

Recommended next steps

  • Follow-up low-dose CT chest at 3 months to assess stability/growth (Lung-RADS 3, high risk) [Lung-RADS 1.1]
  • If stable at 3 months: repeat at 9 and 24 months
  • If growth (volume doubling time < 400 days for solid): tissue sampling (CT-guided biopsy or PET/CT) per multidisciplinary discussion
  • If shrinkage or resolution: most likely benign; can return to baseline screening or annual chest imaging based on smoking risk
  • Review whether patient meets criteria for ongoing annual lung-cancer screening LDCT per USPSTF (eligible if 50–80 yr, ≥ 20 pack-years, quit < 15 years ago)
⚠ Important
This nodule is indeterminate, not diagnosed as cancer. The recommended path is surveillance imaging, not biopsy, because the prior probability of malignancy is low (~5%) and morphology is non-aggressive. Do not lose this follow-up — set a calendar reminder for the 3-month CT.

Key Questions for Your Physician

  • Does this nodule have any features that change the surveillance plan in my case?
  • Given my prior breast cancer, do you want oncology to weigh in?
  • Should we do PET/CT or proceed with the standard surveillance imaging?
  • Do I qualify for annual lung cancer screening, separate from this nodule?
  • Could the cough be related to this nodule, or is another cause more likely?

What This Means for You

The CT scan found a small spot in your right lung (8 mm). The most important thing to understand: most spots of this size are not cancer. In your case, factoring in your age, smoking history, and prior cancer, the estimated chance that this is cancer is around 5% — meaning there is about a 95% chance it is benign.

Because it is too small to biopsy reliably and has no clearly worrying features, the recommended approach is surveillance: a repeat low-dose CT in 3 months to see whether it stays the same, shrinks, or grows. Stability over time is strong evidence that it is benign; significant growth would change the plan.

Importantly, the rest of the scan is reassuring — no enlarged lymph nodes, no other nodules, no signs that suggest spread. Your cough may have a different explanation that should be evaluated separately.

Please make sure the 3-month follow-up CT happens. Set a reminder. If you also qualify for annual lung-cancer screening based on your smoking history, your physician can address that at the same visit.

Analysis Confidence 87%

High confidence in size, morphology, and Lung-RADS/Fleischner categorization. Probability of malignancy is an estimate that incorporates clinical risk factors; longitudinal data (the 3-month CT) is the most informative next step.

References

  1. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology 2017;284(1):228–243.
  2. American College of Radiology. Lung CT Screening Reporting & Data System (Lung-RADS) v1.1. ACR 2019.
  3. McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT. NEJM 2013;369(10):910–9.
  4. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. NEJM 2011;365(5):395–409.
  5. USPSTF Lung Cancer: Screening — final recommendation. JAMA 2021;325(10):962–970.